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Abstract Applying a novel, highly specific and sensitive
immunoabsorption/Western blotting technique we have identified
in vitro in conditioned cell culture medium and in vivo in human
urine different soluble forms of the urokinase-type plasminogen
activator receptor (uPAR/CD87). These include the uPAR
fragment D2D3 and the never before identified domain 1 (D1)
fragment. These forms correspond to fragments previously
characterised as biologically active as inducers of chemotaxis
and cell adhesion. We find that stimulation of U937 cells is
associated with increased uPAR expression, cleavage of surface
uPAR, and release of soluble fragments to the culture medium
suggesting that monocytes are a source of the circulating and
urinary soluble uPAR fragments found in vivo. Our study
demonstrates that potentially biologically active uPAR frag-
ments are produced in the human body, indicating a possible
function in the regulation of not only proteolysis but also signal
transduction related processes. ß 2000 Federation of European
Biochemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
The interaction between urokinase-type plasminogen activa-
tor (uPA) and its receptor (uPAR/CD87) plays a key role in
physiological and pathological processes like cell migration,
tissue remodelling, cancer invasion and metastasis [1,2].
uPAR is composed of three homologous domains (Fig. 1)
and is linked to the cell surface at the carboxy terminus by
a glycosylphosphatidylinositol (GPI) anchor [3]. The amino
terminal domain of uPAR (D1) contains the main uPA-bind-
ing site [4], whereas the next two domains of uPAR (D2D3)
bind the extracellular matrix protein vitronectin [5]. However,
full-size uPAR is required to reach high a⁄nity in both inter-
actions [6^8]. The region linking D1 and D2D3 in uPAR is
prone to cleavage by several proteases including physiologi-
cally relevant enzymes such as neutrophil elastase, plasmin,
and uPA itself [4,9,10]. Chymotrypsin-cleaved or recombinant
soluble uPAR (suPAR) fragments have strong and speci¢c
chemotactic activities on several di¡erent cell types in vitro
[11^14], but the existence and possible biological function of
these fragments in vivo has never been addressed. A variant of
uPAR lacking domain 1 has been identi¢ed on several cul-
tured tumour cell lines, in experimental tumours, and similar
fragments are found in the £uid from human ovarian cysts
[9,15^17]. This D2D3 form of uPAR is formed by the cleav-
age of the full-size molecule [18], however the released soluble
D1 has never been identi¢ed in any cell culture medium or
biological £uid.
We have searched for the presence and possible origin of
suPAR fragments in vivo. Our data demonstrate that uPAR
fragments, including the D2D3 fragment and the never before
identi¢ed D1 fragment, are released from cells and can be
detected in vivo. The data suggest that potentially biologically
active suPAR fragments might actually play a role in pro-
cesses like cell migration and tissue remodelling, not only
locally but also at a distance. The data are thus in accordance
with the growing body of evidence that the uPA/uPAR inter-
action has another function in addition to the regulation of
extracellular proteolysis.
2. Materials and methods
2.1. Materials
Chymotrypsin, PNGaseF, and immobilised streptavidin were from
Roche; 12-O-tetradecanoylphorbol-13-acetate (PMA) was from Sig-
ma; cell culture reagents (RPMI, glutamine, penicillin, streptomycin,
foetal calf serum (FCS), trypsin) were purchased from Gibco-BRL;
anti-uPAR antibodies were kindly provided by Dr. Gunilla HÖyer-
Hansen (Finsen Laboratory, Copenhagen, Denmark); biotinylated
anti-uPA antibody c6 was from Monozyme (Denmark); uPA was a
kind gift from Dr. J. Henkin (Abbott Laboratories, Chicago, IL,
USA).
2.2. Cell culture
U937 cells were cultured in RPMI medium supplemented with 5%
FCS, glutamine (5 mM), penicillin (100 U/ml) and streptomycin (100
Wg/ml). For shedding experiments cells were seeded at 0.2U106/ml in
the presence or absence of 100 ng/ml PMA. At the indicated times the
conditioned medium was collected, centrifuged for 10 min at 14 000
rpm to remove debris and stored at 380‡C. Cells were washed twice
with cold phosphate bu¡ered saline (PBS), lysed in PBS containing
1% Triton X-100 and a cocktail of protease inhibitors (Complete1,
Roche), kept on ice for 1 h, centrifuged for 10 min at 14 000 rpm, and
the supernatants were stored at 380‡C until analysis.
2.3. uPAR enzyme-linked immunosorbent assay (ELISA)
The ELISA used to quantify uPAR antigen in biological samples
has been described previously [19]. The ELISA uses a polyclonal
rabbit anti-human uPAR as catching antibody and a mixture of three
monoclonal antibodies (mAb R2, R3 and R5, see Fig. 1) as detecting
antibodies. It detects full-size uPAR, D1 and D2D3 fragments, as well
as complexes with uPA.
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2.4. Immunoprecipitation, deglycosylation and immunoblotting
Samples were diluted to 1 ml using RIPA bu¡er (0.1% sodium
dodecyl sulfate (SDS), 1% Triton X-100, 1% deoxycholate, 0.15 M
NaCl and 0.05 M Tris^HCl pH 7.6) containing a cocktail of protease
inhibitors and immunoprecipitated for 16 h at 4‡C using biotinylated
monoclonal antibodies (1 Wg), previously immobilised on streptavidin
coated beads (5 Wl). After washing with RIPA bu¡er the absorbed
material was eluted by boiling in non-reducing sample bu¡er and the
proteins size fractionated in 12% SDS^PAGE under non-reducing
conditions. Proteins were transferred to Immobilon-P1 membranes
(Millipore) and probed with a rabbit polyclonal anti-uPAR antibody.
The immune complexes were visualised by incubation with a peroxi-
dase conjugated donkey anti-rabbit antibody (Amersham) and chemo-
luminescent detection (SuperSignal West Dura Extended, Pierce). For
Western blot analysis of deglycosylated uPAR, the washed beads were
added 10 Wl PBS containing 0.5% SDS and 2 mM DTT, and incu-
bated at 95‡C for 3 min. Proteins were deglycosylated by addition of
20 Wl of deglycosylation bu¡er (PBS containing 0.5% Triton X-100
and 15 mM EDTA), 1 unit of peptide-N-glycosidase F (PNGase-F)
and incubated at 37‡C for 2 h. Control samples were treated in the
same manner but did not receive PNGase-F. For Western blotting the
samples were analysed by 12% SDS^PAGE gels under reducing con-
ditions. Antibodies were biotinylated using Sulfo-NHS-Biotin (Pierce)
according to the manufacturers instructions and using a 100-fold mo-
lar excess of biotinylation reagent over antibody.
2.5. Puri¢cation and iodination of recombinant suPAR
Recombinant soluble uPAR was puri¢ed by a⁄nity chromatogra-
phy from conditioned medium of Chinese hamster ovary cells trans-
fected with a mutant uPAR cDNA encoding soluble uPAR (amino
acid 1^276) lacking the GPI anchor [20]. Puri¢ed suPAR was labelled
with 125I using the Iodogen procedure (Pierce Chemicals), resulting in
a speci¢c activity of 80U106 cpm/Wg. For the analysis of suPAR
degradation in urine, aliquots were supplemented with 125I-suPAR
to a concentration of 2 ng/ml and incubated for 24 h at 37‡C. Non-
reducing sample bu¡er was added, and the samples boiled and sepa-
rated by 12% SDS^PAGE. Dried gels were analysed by autoradiog-
raphy at 380‡C using two amplifying screens.
3. Results
3.1. Assay development
To determine the nature of suPAR in biological £uids we
developed a sensitive immunoprecipitation/Western blotting
assay. The assay is based on the capture of the suPAR anti-
gen(s) in the biological sample with biotinylated monoclonal
antibodies recognising epitopes on D1 (mAb R3, Fig. 1) and
D3 (mAb R2), followed by analysis of the absorbed material
by Western blotting using a polyclonal anti-uPAR antibody.
The speci¢city of the assay was veri¢ed using human recombi-
nant suPAR partially digested by chymotrypsin (Fig. 2).
Under mild conditions, chymotrypsin cleaves suPAR speci¢-
cally in the linker region between D1 and D2 [4] generating a
mixture of full-size suPAR, a fragment consisting of domains
D2 and D3 (D2D3), and the free domain D1. From this
mixture the mAb R2, speci¢c for an epitope in domain 3,
precipitated two peptides with approximate molecular weight
of 55 kDa and 35 kDa, i.e. the size of the full-length suPAR
and of the D2D3 fragment. The mAb R3, which recognises an
epitope in domain 1, in addition to the 55 kDa peptide also
precipitated a 16 kDa peptide, the predicted size of the D1
fragment. Inclusion of both R2 and R3 antibodies in the
immunoprecipitation precipitated all three peptides. Another
set of monoclonal antibodies having similar recognition spe-
ci¢city (mAb R4 and mAb R5, see Fig. 1) displayed identical
patterns, con¢rming the identity of these fragments (data not
shown). Although the D1 and D2D3 fragments are present in
equimolar amounts in chymotrypsin digested recombinant su-
PAR, the overall e⁄ciency of detection of the D1 fragment
was several-fold lower than that of the D2D3 fragment. Com-
pared to R2, the R3 antibody was less e⁄cient to immuno-
precipitate full-size suPAR, but indispensable for the detec-
tion of D1.
3.2. suPAR and suPAR fragments in urine and blood
The developed assay identi¢ed three di¡erent uPAR related
polypeptides in urine from healthy volunteers (Fig. 2). The
antibody speci¢city identi¢es the three peptides as full-size
suPAR, D2D3 and D1. In serum, only one peptide corre-
sponding to full-size uPAR was observed. The intensity ratio
between the D1 and the D2D3 fragments in urine was com-
parable to that of chymotrypsin digested suPAR suggesting
that the amounts of these two fragments present in urine are
close to an equimolar ratio. The slight di¡erence in apparent
molecular weight between the fragments present in urine and
those present in the chymotrypsin digestion of recombinant
Fig. 1. Diagram illustrating the domain structure of full-size uPAR
and its proteolytic fragments. uPAR is composed of three domains
(D1, D2, and D3) and is linked to the cell surface by a GPI anchor
attached to D3. Proteolytic cleavage in the linker region between
D1 and D2 results in release of the D1 fragment, leaving behind the
D2D3 fragment on the cell surface. Soluble forms, lacking the GPI
anchor, for both uPAR and D2D3. Monoclonal antibodies speci¢c
for D1 (mAb R3 and R5) and D3 (mAb R2 and R4) are used in
this study to identify the di¡erent uPAR fragments.
Fig. 2. Immunoblot demonstrating the domain structure of suPAR
fragments present in human serum and urine. Serum (0.1 ml) and
urine (0.4 ml) from a healthy male, or partially chymotrypsin di-
gested recombinant human suPAR (Rec. suPAR, 1 ng) was immu-
noprecipitated with mouse monoclonal antibodies R2, R3, R2 plus
R3, or with a control mAb (Ct). The precipitated material was sep-
arated by 12% SDS^PAGE and analysed by Western blotting using
a rabbit polyclonal antibody directed against human uPAR. The mi-
gration of suPAR and the suPAR fragments D2D3 and D1 are in-
dicated on the right side of the panel and the position of molecular
weight markers on the left side of the panel.
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suPAR is due to the di¡erence in molecular size and glyco-
sylation of the recombinant protein.
3.3. suPAR and suPAR fragments are stable in urine
The abundant presence of suPAR fragments in urine could
re£ect the generation of the fragments in the urine by proteo-
lytic degradation of full-length suPAR. We therefore analysed
whether the pattern of suPAR fragments in urine samples was
stable when stored for 24 h at di¡erent temperatures (320‡C,
4‡C, 20‡C and 37‡C), or when subjected to repeated freeze/
thaw cycles in the presence and absence of protease inhibitors
(Fig. 3A). The pattern of suPAR fragments was found to be
minimally a¡ected by the storage temperature, thawing and
by the presence or absence of protease inhibitors. Finally,
when radiolabelled recombinant suPAR was added to 10 in-
dependent urine samples, minimal degradation after incuba-
tion for 24 h at 37‡C was observed (Fig. 3B). We conclude
that the presence of D2D3 and D1 fragments in the urinary
compartment is unlikely to be due to urinary degradation of
full-size suPAR.
3.4. U937 cells shed soluble uPAR and uPAR fragments into
the growth medium
The ¢nding that suPAR and suPAR fragment are stable in
urine suggests that the presence of these fragments in this
compartment re£ects proteolytic cleavage and shedding of
uPAR occurring in distant parts of the organism. This possi-
bility prompted us to investigate whether uPAR fragments are
produced and released by cell types known to express uPAR.
For this purpose we analysed the cleavage and shedding of
uPAR in cultured U937 cells in the presence or absence of the
phorbol ester PMA (Fig. 4). Measured by ELISA the amount
of cellular uPAR in untreated cells was relatively constant
during the experiment, while PMA induced a strong and per-
sistent increase, as expected, visible already between 24 and
72 h (Fig. 4A, top). Throughout culture suPAR antigen ac-
cumulated in the medium indicating a continuous shedding of
uPAR from the cells to the medium (Fig. 4B, top). The
amount of uPAR antigen released from non-treated cells dur-
ing the ¢rst 24 h of culture (0.4 ng/106 cells) corresponded
approximately to a complete turnover of cellular uPAR in
24 h. The release rate was much higher in PMA stimulated
cells (6.1 ng/106 cells) corresponding to a turnover rate of
cellular uPAR of approximately 3.5 h.
To determine the molecular structure of the uPAR antigen
present in the cell lysates and in the conditioned medium we
performed immunoprecipitation experiments using a combi-
Fig. 4. uPAR antigen in U937 cell lysates (A) and in conditioned
media (B). U937 cells were plated in the absence or presence of 100
nM PMA and after 24, 48 and 72 h the cells and conditioned media
were harvested. The total level of uPAR antigen in the cell lysates
and conditioned medium was measured by ELISA, and the molecu-
lar structure determined by immunoprecipitation using a combina-
tion of the R2 and R3 antibodies as described in the legend to Fig.
2. The positions of molecular weight markers, full-length uPAR,
cleaved uPAR (D2D3) and the released domain 1 (D1) are indi-
cated. The panel marked with an asterisk (*) is a long exposure of
the lane containing conditioned medium from U937 cells treated
with PMA for 72 h.
Fig. 3. Stability of suPAR and suPAR fragments in human urine.
A: Aliquots (0.2 ml) of freshly obtained urine were incubated for
24 h at the indicated temperatures in the presence (+) or absence
(3) of protease inhibitors (1 mM PMSF and 5 mM EDTA). One
sample (*) was subjected to ¢ve freeze/thaw cycles. The samples
were analysed by immunoprecipitation/Western blotting as described
in the legend to Fig. 4. B: Urine samples from 10 di¡erent individu-
als were added 125I-suPAR to 2 ng/ml and incubated for 24 h at
37‡C after which the samples were analysed by 12% SDS^PAGE
and autoradiography. As a control 125I-suPAR was incubated in
bu¡er (PBS) in the absence (no) or presence of 1 WM uPA (uPA).
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nation of R2 and R3 monoclonal antibodies (Fig. 4A and B,
bottom). In non-stimulated cells a prominent band with a
molecular weight around 50^55 kDa representing full-length
uPAR could be observed both in cell lysates and in condi-
tioned media. Stimulation with PMA resulted in a strong in-
crease in the intensity of this band and the appearance of
shorter polypeptides. The intense band with a molecular
weight around 35 kDa suggests a cleaved receptor composed
of domains 2 and 3 (D2D3), and could be observed in both
the cell lysates and in the conditioned media. Long exposure
of the blots revealed the presence of a fast migrating band in
conditioned medium from PMA stimulated cells with a mo-
lecular weight around 15 kDa possibly representing the do-
main 1 fragment (D1). Despite long exposures, the D1 band
was never observed in cell lysates (not shown) in accordance
with the model that D1 is released from the cell surface upon
receptor cleavage.
To unequivocally identify the di¡erent uPAR polypeptides
present in the U937 conditioned media we selectively immu-
noprecipitated conditioned medium from PMA stimulated
cells with the above characterised panel of di¡erent monoclo-
nal antibodies (Fig. 5). Antibodies recognising domain 3 (R2
and R4) precipitated the two larger fragments in accordance
with the identity of these bands being full-length suPAR and
D2D3. The antibody against D1 (R3) precipitated full-length
uPAR and the small 15 kDa fragment but not the D2D3
band, con¢rming the identity of these peptides to be full-
length uPAR and the D1 fragment. Full-length uPAR could
furthermore be precipitated with a monoclonal antibody
against uPA (mAb c6) demonstrating that the receptor in
the conditioned medium, at least partially, is associated with
uPA. A control antibody did not precipitate any of these
proteins. The highly heterogeneous glycosylation of uPAR
causes a ‘smeary’ appearance of uPAR and uPAR fragments
in Western blotting preventing a good separation of full-
length uPAR and the D2D3 fragment. To eliminate this prob-
lem we performed Western blotting on immunoprecipitates
that had been reduced, denatured, and deglycosylated. Indeed,
the migration pattern of uPAR, D2D3 and D1 after deglyco-
sylation was in complete accordance with the molecular
weights based on the cDNA derived amino acid sequence of
uPAR and a cleavage in the region between domains 1 and 2.
Also, the separation of full-length uPAR and D2D3 was ex-
cellent under these conditions allowing an accurate identi¢ca-
tion of the di¡erent uPAR fragments.
4. Discussion
uPA and uPAR are known to be involved in proteolytic
processes during wound healing and cell migration by activat-
ing plasminogen activation. Recently however, a number of
studies have indicated that there might be additional impor-
tant functions for this system, with uPAR as the key compo-
nent [2,21].
uPAR is able to interact with several soluble and membrane
proteins other than uPA, e.g. vitronectin, integrins, and
thrombospondin. Even though major binding sites for one
or more of these ligands reside in one of the three domains
of uPAR, the full-size structure appears to be essential for
high a⁄nity [7,8,22]. Thus, the ¢nding that uPAR is cleaved
under physiological conditions implies interesting consequen-
ces for the regulation of extracellular proteolysis and cell ad-
hesion. First, the abolished binding of uPA is expected to
result in a reduced potential of the cell to promote plasmino-
gen activation [9]. Second, abolished vitronectin binding re-
duces uPAR dependent cell adhesion to this substrate [8,23].
Cleavage of uPAR however, will not only bear negative in£u-
ence on its function. The part of uPAR that has been found to
be susceptible to cleavage is the linker region between do-
mains 1 and 2 [4,9,10]. The chemotactic properties transduced
by the binding of uPA to uPAR are in fact mediated by an
epitope within this linker region of uPAR, which is uncovered
by uPA binding or by cleavage [11,13]. Although soluble D1
or D2D3 have not previously been found in conditioned me-
dia, or in blood, our data demonstrates for the ¢rst time that
these fragments are indeed released from cells and can be
found in vivo.
The question why in serum the domains D1 and D2D3
were not found, still remains to be answered. Their half-life
in the circulation may be too short, possibly due to the re-
duced molecular size or by impaired ability to bind stabilising
molecules like for instance uPA and/or vitronectin. Indeed,
the possibility that full-length suPAR is associated with other
molecules in serum and urine is strongly supported by our
data. The R3 antibody is known not to bind suPAR associ-
ated with uPA or vitronectin [7,24] and fails to e⁄ciently
precipitate full-length suPAR from urine and serum (Fig. 2).
Our data suggest that the type of uPAR fragments present
in urine might re£ect the cleavage state of uPAR in tissues
distant from the urinary compartment. It has been suggested
that uPAR cleavage occurs predominantly in areas of tissue
remodelling where both uPAR and uPA are expressed at high
levels [18]. The detection and molecular characterisation of
these fragments in urine and blood might therefore re£ect
remodelling phenomena in physiological or pathological proc-
esses in which the uPA/uPAR system is involved, including
cancer.
Fig. 5. Molecular structure of uPAR fragments in conditioned me-
dium from U937 cells. Conditioned medium obtained from PMA
stimulated U937 cells was either immunoprecipitated with antibodies
recognising uPAR domain 3 (R2 and R4), or uPAR domain 1 (R3),
or an anti-uPA antibody (c6), or an irrelevant antibody (Ct). After
washing, the precipitates were denatured, reduced and treated for
2 h without (A) of with PNGase-F (B) and analysed by Western
blotting.
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